Tesaro Inc

Tesaro — Q4 2015 Earnings Presentation

22 slides from Tesaro's earnings presentation, Feb 25, 2016

  1. Slide 1: Safe Harbor Statement

    Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private S

  2. Slide 2: Lonnie Moulder, Chief Executive Officer

    Lonnie Moulder Chief Executive Officer

  3. Slide 3: 2015 Was a Pivotal Year for TESARO

    2015 Was a Pivotal Year for TESARO Key Accomplishments Established Field Organization Launched 1st Commercial Product Advanced Product Pipeline Expanded Executive Team Full-scale, experienced oncology sales team and corporate accounts teams Medical science liaison, nurse educator teams A valuable as

  4. Slide 4: VARUBI: TESARO's First Marketed Product

    Approved by FDA on September 1, 2015 1 Provides protection from CINV for the full delayed risk period (25–120 hours) 2 Single oral dose administration just prior to chemotherapy 6 Included in NCCN® Antiemesis Guidelines with a Category 1 Level of Evidence and Consensus for MEC and HEC 3 No dose adju

  5. Slide 5: Strategy to Drive Growth

    Strategy to Drive Growth VARUBI®: Establish Oral, Take Share Establish IV, Take Share Grow NK-1 Market Opportunity Each Initial VARUBI Dose May Lead to An Additional Three to Four Doses During an Average Course of Chemotherapy Year 1 Year 2 Year 3 Year 4 Volume Oral IV

  6. Slide 6: Commercial Launch Update: The First Weeks

    Commercial Launch Update: The First 10 Weeks Data as of January 31, 2016; IOD: In-office dispensing; RA: receptor antagonist 1 Source: Company estimates; wholesaler and specialty pharmacy data 2 Source: IMS DDD data analysis and Company estimates 3 Source: Managed Markets Insight & Technology, LLC a

  7. Slide 7: Tim Pearson, Chief Financial Officer

    Tim Pearson Chief Financial Officer

  8. Slide 8: Q4 2015 Financial Results

    Q4 2015 Financial Results Unless otherwise noted, figures are in thousands, except for per-share data. Three Months Ended December 31, 2014 Three Months Ended December 31, 2015 License Revenue -- $230 Expenses: Cost of Sales -- $268 Research & Development $29,814 42,852 Selling, General & Administra

  9. Slide 9: Mary Lynne Hedley, Ph.D., President & Chief Operating Officer

    Mary Lynne Hedley, Ph.D. President & Chief Operating Officer

  10. Slide 10: A Balanced Portfolio of Product Candidates

    A Balanced Portfolio of Product Candidates mAb: Monoclonal antibody * In collaboration with ENGOT, the European Network for Gynaecological Oncological Trial groups ** In collaboration with the Hoosier Cancer Research Network *** In collaboration with SARC, the Sarcoma Alliance for Research through C

  11. Slide 11: Development Programs Update

    Development Programs Update Bioequivalence trial successfully achieved its primary endpoint Planned clinical development program is complete NDA preparations on track to support submission in Q1 2016 Anticipate a 12-month FDA review Rolapitant IV Patient treatment continues in the Phase 3 NOVA trial

  12. Slide 12: Development Programs Update

    Development Programs Update Bioequivalence trial successfully achieved its primary endpoint Planned clinical development program is complete NDA preparations on track to support submission in Q1 2016 Anticipate a 12-month FDA review Rolapitant IV Patient treatment continues in the Phase 3 NOVA trial

  13. Slide 13: NOVA Trial: Study Data Anticipated in Q2

    Phase 3 NOVA Trial NOVA Study Data Anticipated in Q2 Prospectively defined statistical analysis of PFS in the HRD population >90% power PFS: Progression free survival; HRD: Homologous recombination deficiency gBRCAmut Endpoint Assessment Niraparib 300 mg Placebo Non-gBRCAmut / HRD Endpoint Assessmen

  14. Slide 14: Phase 3 Trials in Recurrent Platinum Sensitive Ovarian Cancer Support NOVA Assumptions

    Median PFS in chemotherapy-free maintenance period is < 6 months Phase 3 Trials in Recurrent Platinum Sensitive Ovarian Cancer Support NOVA Assumptions *Maintenance Period initiates ~6w post discontinuation of chemotherapy (6 x 21day cycles) Source: ICON4, CALYPSO, AGO-OVAR 2.5 and OCEANS trials. Ad

  15. Slide 15: Additional Monotherapy and Combination Trials

    Additional Monotherapy and Combination Trials NIRAPARIB: QUADRA trial of niraparib for ovarian cancer treatment PRIMA trial of niraparib for first line ovarian cancer BRAVO trial of niraparib for patients with gBRCAmut advanced/metastatic breast cancer treatment Niraparib + bevacizumab (AVANOVA) com

  16. Slide 16: Development Programs Update

    Development Programs Update NDA: New Drug Application IND: Investigational New Drug application mAb: Monoclonal Antibody IV: Intravenous I-O: Immuno-oncology Bioequivalence trial successfully achieved its primary endpoint Planned clinical development program is complete NDA preparations on track to

  17. Slide 17: Lonnie Moulder, Chief Executive Officer

    Lonnie Moulder Chief Executive Officer

  18. Slide 18: Strong Financial and Strategic Position

    Strong Financial and Strategic Position TESARO: First Commercial Product Launched Portfolio Addresses Large Markets Balanced Product Pipeline Strong Financial Position Proven Management Team CINV: >$1B Ovarian: $4B Breast: $1B Several Programs, Early to Late Stage, Small Molecules & Biologics ~$230M

  19. Slide 19: TESARO: 2016 Goals

    T E S A R O : 2016 Goals Continue to execute on the U.S. VARUBI commercial launch Submit the NDA for IV rolapitant in Q1 2016 Submit the oral rolapitant MAA to the EMA in Q2 2016 VARUBI® (rolapitant) Initiate enrollment in the PRIMA trial in Q1 2016 Initiate enrollment in the niraparib/KEYTRUDA® com

  20. Slide 20: TESARO 2016 Goals

    TESARO 2016 Goals > Continue to execute on the U.S. VARUBI commercial launch > Submit the NDA for IV rolapitant in Q1 2016 > Submit the oral rolapitant MAA to the EMA in Q2 2016 VARUBI® (rolapitant) > Initiate enrollment in the PRIMA trial in Q1 2016 > Initiate enrollment in the niraparib/KEYTRUDA®

  21. Slide 21: Fourth-Quarter 2015 Results

    Fourth-Quarter 2015 Results February 25, 2016

  22. Slide 22: TESARO Fourth-Quarter 2015 Results

    w TESARO Fourth-Quarter 2015 Results February 25, 2016

TESARO — Q4 2015 Earnings Presentation on 6ix